GHK-Cu
PeptideCopper tripeptide-1
Compounding status of GHK-Cu — FDA 503A bulks-list standing, PCAC review history, and state overlays. Each entry links to its source; entries marked reported rest on trade-press coverage until the FDA primary record posts.
Current federal standing
Not compoundable under 503A
GHK-Cu is not on the 503A Bulks List. FDA has scheduled it for the next Pharmacy Compounding Advisory Committee review — by the end of February 2027 (exact date not yet posted). FDA PCAC ↗
Federal history
No federal status has been published for GHK-Cu yet. We’re monitoring the Federal Register and FDA/PCAC; a standing appears here only with its source document.
State overlays
No state-specific position on GHK-Cu tracked yet. State boards hold independent authority; legislation is monitored via LegiScan and board positions are added as they are verified.
Track GHK-Cu changes
Get the free weekly Brief — FDA and state moves on peptide & GLP-1 compounding, with the source and the date. Members are alerted for their states as soon as a change is published.
Get the free Brief →← All substances · Informational monitoring from public government sources — not legal or medical advice. No efficacy claims.